Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02472418 | Two Dose Levels of DFN-15 vs. Placebo in Patients With Migraine Headaches | PHASE2 | COMPLETED | 63 | — | — | Jun 5, 2015 | May 5, 2016 | May 22, 2018 | 6 | United States |
Percentage of subjects who are migraine headache free at 2 hours after taking study drug administration
| Arm | Type | Description |
|---|---|---|
| DFN-15 120 mg (treatment A) | EXPERIMENTAL | DFN-15 120 mg (treatment A) |
| DFN-15 240 mg (treatment B) | EXPERIMENTAL | DFN-15 240 mg (treatment B) |
| Placebo (treatment C) | PLACEBO_COMPARATOR | Placebo (treatment C) |
| Name | Type | Description |
|---|---|---|
| DFN-15 Dose A (treatment A) | DRUG | DFN-15 Dose A administered |
| DFN-15 Dose B (treatment B) | DRUG | DFN-15 Dose B administered |
| Placebo (treatment C) | OTHER | Placebo administered |
Inclusion Criteria: 1. Patients with a history of episodic migraine (as defined by International Classification of Headache Disorders \[ICHD\]-228) who experience an average of 2 to 6 migraine attacks a month for the past 12 months with no more than 14 headache days per month, and with at least 48 ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AbbVie, Inc. | ABBV | 15 | PHASE3 | Atogepant, Topiramate, Ubrogepant, MEDI0618 |
| Pfizer Inc. | PFE | 9 | PHASE3 | Rimegepant, Rimegepant/BHV3000, Zavegepant, Various, Rimegepant for acute migraine treatment |
| Eli Lilly and Company | LLY | 2 | PHASE3 | Galcanezumab |
| Amgen Inc. | AMGN | 2 | PHASE3 | Erenumab Dose 1, erenumab-aooe |
| Ki Health Partners. LLC | RVNC | 1 | — | Daxibotulinumtonix A |